MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

34.09 -0.84

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

33.37

Max

34.36

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+64.63% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	941M 2.6B
Vorige openingsprijs	34.93
Vorige sluitingsprijs	34.09

Nieuwssentiment

By Acuity

100%

338 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 apr 2026, 23:27 UTC

Belangrijke Nieuwsgebeurtenissen

BHP Expects Annual Copper Output in Upper Half of Guidance, Finishes China Iron-Ore Negotiations

21 apr 2026, 23:27 UTC

Populaire aandelen

Stocks to Watch: Sonoco Products, Adobe, Manhattan Associates, Target Hospitality

21 apr 2026, 23:02 UTC

Winsten

Correction to Capital One Financial 1Q Earnings Article

21 apr 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 apr 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline as Hopes for U.S.-Iran Peace Talks Fade

21 apr 2026, 23:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Market Talk Roundup: Latest on U.S. Politics

21 apr 2026, 23:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher After Trump Says U.S. Will Extend Cease-Fire Deadline -- Market Talk

21 apr 2026, 23:32 UTC

Winsten

America Movil 1Q EBITDA MXN94.5B, Up 3.8% on Year >AMX

21 apr 2026, 23:30 UTC

Winsten

America Movil 1Q Rev MXN236.84B, Up 2.1% on Year >AMX

21 apr 2026, 23:28 UTC

Winsten

America Movil 1Q Net MXN23.4B Vs. Net MXN18.7B >AMX

21 apr 2026, 23:16 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol Entered 2Q With Hedge Book Positioned to Mitigate Volatility

21 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol Entered 2Q With Broad-Based Momentum

21 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol: Suitable Crudes for Lytton Remain Available in Market

21 apr 2026, 23:14 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol: Crude Supplies Secured Into July

21 apr 2026, 23:14 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol: Fuel Supplies Secured Until at Least End of May

21 apr 2026, 23:13 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol: Well Placed for Crude, Product Supply Prior to Iran Conflict

21 apr 2026, 23:13 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol 1Q Lytton Refinery Production 1.43 Billion Liters

21 apr 2026, 23:12 UTC

Belangrijke Nieuwsgebeurtenissen

Ampol 1Q Lytton Refiner Margin US$25.45/Bbl

21 apr 2026, 22:54 UTC

Marktinformatie

Sell America Trade Could Gain Momentum If Fed Uncertainty Unresolved -- Market Talk

21 apr 2026, 22:49 UTC

Belangrijke Nieuwsgebeurtenissen

BHP 3Q Average Realized Energy Coal Price $105.61/Ton, Up 10% On-Quarter

21 apr 2026, 22:49 UTC

Belangrijke Nieuwsgebeurtenissen

BHP 3Q Average Realized Steelmaking Coal Price $226.76/Ton, Up 15% On-Quarter

21 apr 2026, 22:48 UTC

Belangrijke Nieuwsgebeurtenissen

BHP 3Q Average Realized Iron Ore Price $85.35/Ton, Flat On-Quarter

21 apr 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Alliance Portfolio Is Comprised of Five Plants: Batavia, Hillburn, Massena, Shoemaker and Sterling

21 apr 2026, 22:48 UTC

Belangrijke Nieuwsgebeurtenissen

BHP 3Q Average Realized Copper Price $5.86/Pound, Down 1% On-Quarter

21 apr 2026, 22:48 UTC

Acquisities, Fusies, Overnames

PowerTransitions to Buy 323 MW of Power Generation Assets in New York State From Alliance Energy Group

21 apr 2026, 22:46 UTC

Belangrijke Nieuwsgebeurtenissen

BHP: Has Concluded Iron Ore Sales Contract Negotiations With China Mineral Resources Group

21 apr 2026, 22:45 UTC

Belangrijke Nieuwsgebeurtenissen

BHP: Pampa Norte Production Down on Ore Complexity, Variation; Declining Grades

21 apr 2026, 22:45 UTC

Belangrijke Nieuwsgebeurtenissen

BHP: Escondida Concentrator Investment Estimated Between $4.4 Billion-$5.9 Billion

21 apr 2026, 22:44 UTC

Belangrijke Nieuwsgebeurtenissen

BHP: Escondida Concentrator Project Seen Facing FID in 2027-28

21 apr 2026, 22:42 UTC

Belangrijke Nieuwsgebeurtenissen

BHP CEO: Centralized Procurement, Low-cost Operations Help Buffer Industry Wide Cost Pressures

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

64.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 56.6 USD 64.63%

Hoogste 90 USD

Laagste 34 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.